Literature DB >> 15118606

Choice and dose of corticosteroid for antenatal treatments.

Alan H Jobe1, Roger F Soll.   

Abstract

Although antenatal glucocorticoids are standard of care for women at risk of preterm delivery before 32 to 34 weeks' gestation, the choice and dosing of the corticosteroid has not been standardized. An analysis of the trial data demonstrates that the risk of neonatal death is decreased with betamethasone, but not dexamethasone. Other clinical data also indicate that betamethasone is the drug of choice for antenatal treatment. The pharmacology of the corticosteroids suggests that a lower total glucocorticoid dose per treatment may be as effective as the current treatment recommendations. However, a change from current practice will require further randomized controlled trials.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15118606     DOI: 10.1016/j.ajog.2004.01.044

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  46 in total

1.  Kinetics of betamethasone and fetal cardiovascular adverse effects in pregnant sheep after different doses.

Authors:  Matthias Schwab; Turhan Coksaygan; Mahesh N Samtani; William J Jusko; Peter W Nathanielsz
Journal:  Obstet Gynecol       Date:  2006-09       Impact factor: 7.661

2.  Prenatal maternal cortisol concentrations predict neurodevelopment in middle childhood.

Authors:  Elysia Poggi Davis; Kevin Head; Claudia Buss; Curt A Sandman
Journal:  Psychoneuroendocrinology       Date:  2016-10-15       Impact factor: 4.905

3.  The impact of drug metabolizing enzyme polymorphisms on outcomes after antenatal corticosteroid use.

Authors:  David M Haas; Amalia S Lehmann; Todd Skaar; Santosh Philips; Catherine L McCormick; Kyle Beagle; Scott J Hebbring; Jessica Dantzer; Lang Li; Jeesun Jung
Journal:  Am J Obstet Gynecol       Date:  2012-02-28       Impact factor: 8.661

4.  Association of Short Antenatal Corticosteroid Administration-to-Birth Intervals With Survival and Morbidity Among Very Preterm Infants: Results From the EPICE Cohort.

Authors:  Mikael Norman; Aurelie Piedvache; Klaus Børch; Lene Drasbek Huusom; Anna-Karin Edstedt Bonamy; Elizabeth A Howell; Pierre-Henri Jarreau; Rolf F Maier; Ole Pryds; Liis Toome; Heili Varendi; Tom Weber; Emilija Wilson; Arno Van Heijst; Marina Cuttini; Jan Mazela; Henrique Barros; Patrick Van Reempts; Elizabeth S Draper; Jennifer Zeitlin
Journal:  JAMA Pediatr       Date:  2017-07-01       Impact factor: 16.193

5.  Modification of histogenetic processes in rat nervous tissue after administration of dexamethasone during prenatal development.

Authors:  D E Korzhevskii; E G Gilerovich; L I Khozhai; I P Grigor'ev; V A Otellin
Journal:  Neurosci Behav Physiol       Date:  2006-06

Review 6.  Minireview: the impact of antenatal therapeutic synthetic glucocorticoids on the developing fetal brain.

Authors:  Melanie E Peffer; Janie Y Zhang; Leah Umfrey; Anthony C Rudine; A Paula Monaghan; Donald B DeFranco
Journal:  Mol Endocrinol       Date:  2015-03-12

7.  Betamethasone for lung maturation: testing dose and formulation in fetal sheep.

Authors:  Alan H Jobe; Timothy J M Moss; Ilias Nitsos; Machiko Ikegami; Suhas G Kallapur; John P Newnham
Journal:  Am J Obstet Gynecol       Date:  2007-11       Impact factor: 8.661

Review 8.  Pregnancy outcomes in patients with autoimmune diseases and anti-Ro/SSA antibodies.

Authors:  Antonio Brucato; Rolando Cimaz; Roberto Caporali; Véronique Ramoni; Jill Buyon
Journal:  Clin Rev Allergy Immunol       Date:  2011-02       Impact factor: 8.667

Review 9.  Effects of antenatal corticosteroids on the hypothalamic-pituitary-adrenocortical axis of the fetus and newborn: experimental findings and clinical considerations.

Authors:  Feizal Waffarn; Elysia Poggi Davis
Journal:  Am J Obstet Gynecol       Date:  2012-06-13       Impact factor: 8.661

Review 10.  Effects of antenatal glucocorticoids on the developing brain.

Authors:  Ross Carson; A Paula Monaghan-Nichols; Donald B DeFranco; Anthony C Rudine
Journal:  Steroids       Date:  2016-06-23       Impact factor: 2.668

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.